Most Read Articles
Stephen Padilla, 21 hours ago
Treatment with oral thrombopoietin receptor agonist eltrombopag leads to similar platelet counts in patients with chronic immune thrombocytopaenia (cITP) and persistent (per)ITP, according to the results of phase III (EXTEND) and IV studies presented at the 23rd Congress of the European Hematology Association (EHA 2018) held in Stockholm, Sweden.
Pearl Toh, 3 days ago
Lonely people were twice as likely to die from any cause than people who did not feel lonely, according to a study based on a national survey presented at the recent EuroHeartCare 2018 in Dublin, Ireland. Also, loneliness is associated with poorer patient-reported outcomes in terms of mental and physical health in patients with heart disease.
6 days ago
Higher activity of plasma xanthine oxidase appears to be linked to insulin resistance and liver dysfunction among type 2 diabetes mellitus (T2DM) patients with metabolic syndrome (MetS), according to a recent Japan study.
6 days ago
Use of quetiapine among critically ill patients rarely leads to corrected QT (QTc) interval prolongation, reports a new study.

IBI-10090 dexamethasone drug-delivery suspension safe, effective for postoperative inflammation

03 Jun 2018

An anterior chamber intracameral dexamethasone drug-delivery suspension (IBI-10090) at concentrations of 342 and 517 μg is safe and effective in treating postoperative inflammation in patients undergoing cataract surgery, according to a study. In addition, IBI-10090 may replace corticosteroid drop installation in these patients.

A total of 394 patients undergoing unilateral cataract surgery by phacoemulsification were randomized to receive 5-μl injections of placebo or 5-μl injections of 342 or 517 μg IBI-10090 dexamethasone drug delivery suspension injected into the anterior chamber. All patients were followed for 90 days after surgery.

Anterior chamber cell (ACC) clearing (ACC score of 0) in the study eye at postoperative day (POD) 8 was the primary outcome. Secondary outcomes were anterior chamber flare and ACC plus flare clearing in the study eye. The investigators also assessed ocular and nonocular adverse events.

More eyes in the 342- and 517-μg IBI-10090 treatment groups (63.1 percent and 66.0 percent, respectively) vs the placebo group (25.0 percent) achieved ACC clearing at POD 8 (p<0.001). Likewise, more eyes in the 342- and 517-μg treatment groups (92.4 percent and 89.1 percent, respectively) vs the placebo group (63.8 percent) achieved anterior chamber flare clearing at POD 8 (p<0.001).

Moreover, anterior chamber cell plus flare clearing at POD 8 was achieved in 63.1 percent and 67.3 percent of eyes receiving 342- and 517-μg IBI-10090, respectively, and in 33.8 percent of eyes receiving placebo (p<0.001).

Adverse events were comparable among the three groups, and there were no reports of serious ocular adverse events up to POD 90.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 21 hours ago
Treatment with oral thrombopoietin receptor agonist eltrombopag leads to similar platelet counts in patients with chronic immune thrombocytopaenia (cITP) and persistent (per)ITP, according to the results of phase III (EXTEND) and IV studies presented at the 23rd Congress of the European Hematology Association (EHA 2018) held in Stockholm, Sweden.
Pearl Toh, 3 days ago
Lonely people were twice as likely to die from any cause than people who did not feel lonely, according to a study based on a national survey presented at the recent EuroHeartCare 2018 in Dublin, Ireland. Also, loneliness is associated with poorer patient-reported outcomes in terms of mental and physical health in patients with heart disease.
6 days ago
Higher activity of plasma xanthine oxidase appears to be linked to insulin resistance and liver dysfunction among type 2 diabetes mellitus (T2DM) patients with metabolic syndrome (MetS), according to a recent Japan study.
6 days ago
Use of quetiapine among critically ill patients rarely leads to corrected QT (QTc) interval prolongation, reports a new study.